347 related articles for article (PubMed ID: 31923763)
1. Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam.
Savage TE; Sourbron J; Bruno PL; Skirvin LA; Wolper ES; Anagnos CJ; Thiele EA
Epilepsy Res; 2020 Feb; 160():106263. PubMed ID: 31923763
[TBL] [Abstract][Full Text] [Related]
2. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.
Geffrey AL; Pollack SF; Bruno PL; Thiele EA
Epilepsia; 2015 Aug; 56(8):1246-51. PubMed ID: 26114620
[TBL] [Abstract][Full Text] [Related]
3. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.
Patel S; Grinspoon R; Fleming B; Skirvin LA; Wade C; Wolper E; Bruno PL; Thiele EA
Epilepsia; 2021 Jul; 62(7):1594-1603. PubMed ID: 34050682
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Porcari GS; Fu C; Doll ED; Carter EG; Carson RP
Epilepsy Behav; 2018 Mar; 80():240-246. PubMed ID: 29429908
[TBL] [Abstract][Full Text] [Related]
5. Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.
Gaston TE; Bebin EM; Cutter GR; Ampah SB; Liu Y; Grayson LP; Szaflarski JP;
Epilepsy Behav; 2019 Sep; 98(Pt A):201-206. PubMed ID: 31382177
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.
Devinsky O; Thiele EA; Wright S; Checketts D; Morrison G; Dunayevich E; Knappertz V
Acta Neurol Scand; 2020 Dec; 142(6):531-540. PubMed ID: 32592183
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis.
Lattanzi S; Trinka E; Striano P; Zaccara G; Del Giovane C; Nardone R; Silvestrini M; Brigo F
Epilepsia; 2020 Jun; 61(6):1090-1098. PubMed ID: 32452532
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic synergism contributes to the antiseizure action of cannabidiol and clobazam.
Rana RR; Rajasekaran K; Knappertz V; Gray RA
Exp Neurol; 2023 Feb; 360():114286. PubMed ID: 36442674
[TBL] [Abstract][Full Text] [Related]
9. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials.
Bialer M; Perucca E
Epilepsia; 2020 Jun; 61(6):1082-1089. PubMed ID: 32452568
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.
Hess EJ; Moody KA; Geffrey AL; Pollack SF; Skirvin LA; Bruno PL; Paolini JL; Thiele EA
Epilepsia; 2016 Oct; 57(10):1617-1624. PubMed ID: 27696387
[TBL] [Abstract][Full Text] [Related]
11. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Talwar A; Estes E; Aparasu R; Reddy DS
Exp Neurol; 2023 Jan; 359():114238. PubMed ID: 36206805
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.
Gaston TE; Ampah SB; Martina Bebin E; Grayson LP; Cutter GR; Hernando K; Szaflarski JP;
Epilepsy Behav; 2021 Apr; 117():107862. PubMed ID: 33667843
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
Gunning B; Mazurkiewicz-Bełdzińska M; Chin RFM; Bhathal H; Nortvedt C; Dunayevich E; Checketts D
Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol in treatment of refractory epileptic spasms: An open-label study.
Herlopian A; Hess EJ; Barnett J; Geffrey AL; Pollack SF; Skirvin L; Bruno P; Sourbron J; Thiele EA
Epilepsy Behav; 2020 May; 106():106988. PubMed ID: 32169600
[TBL] [Abstract][Full Text] [Related]
17. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Devinsky O; Patel AD; Thiele EA; Wong MH; Appleton R; Harden CL; Greenwood S; Morrison G; Sommerville K;
Neurology; 2018 Apr; 90(14):e1204-e1211. PubMed ID: 29540584
[TBL] [Abstract][Full Text] [Related]
18. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.
Sands TT; Rahdari S; Oldham MS; Caminha Nunes E; Tilton N; Cilio MR
CNS Drugs; 2019 Jan; 33(1):47-60. PubMed ID: 30460546
[TBL] [Abstract][Full Text] [Related]
20. A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam.
VanLandingham KE; Crockett J; Taylor L; Morrison G
J Clin Pharmacol; 2020 Oct; 60(10):1304-1313. PubMed ID: 32652616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]